Limits...
A history of the term "DMARD".

Buer JK - Inflammopharmacology (2015)

Bottom Line: It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word.Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART).The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

View Article: PubMed Central - PubMed

Affiliation: Department of Social Anthropology, University of Oslo, Blindern, Postboks 1091, 0317, Oslo, Norway, j.k.buer@sai.uio.no.

ABSTRACT
The article outlines a history of the concept of "disease-modifying antirheumatic drugs" or DMARDs--from the emergence in the 1970s of the idea of drugs with decisive long-term effects on bone erosion in rheumatoid arthritis (RA), through the consolidation and popularisation in the term DMARD in 1980s and 1990s. It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word. Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART). The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

No MeSH data available.


Related in: MedlinePlus

Title page of one of the three publications, in PubMed that had the initialism SAARD in their title. With permission from Capell and Brzeski (1992), Annals of the Rheumatic Diseases, BMJ Publishing Group Ltd
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4508364&req=5

Fig5: Title page of one of the three publications, in PubMed that had the initialism SAARD in their title. With permission from Capell and Brzeski (1992), Annals of the Rheumatic Diseases, BMJ Publishing Group Ltd

Mentions: As for the term’s initialism (SAARD), it figured in the title of three publications (Danis et al. 1991; Capell and Brzeski 1992; van Gestel et al. 1997). In all three cases, the term figured in parenthesis following the full phrase “slow-acting anti-rheumatic drugs”, indicative of use as initialism; it was not standing alone as an independent word, as the term DMARD had come to do (Fig. 5).Fig. 5


A history of the term "DMARD".

Buer JK - Inflammopharmacology (2015)

Title page of one of the three publications, in PubMed that had the initialism SAARD in their title. With permission from Capell and Brzeski (1992), Annals of the Rheumatic Diseases, BMJ Publishing Group Ltd
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4508364&req=5

Fig5: Title page of one of the three publications, in PubMed that had the initialism SAARD in their title. With permission from Capell and Brzeski (1992), Annals of the Rheumatic Diseases, BMJ Publishing Group Ltd
Mentions: As for the term’s initialism (SAARD), it figured in the title of three publications (Danis et al. 1991; Capell and Brzeski 1992; van Gestel et al. 1997). In all three cases, the term figured in parenthesis following the full phrase “slow-acting anti-rheumatic drugs”, indicative of use as initialism; it was not standing alone as an independent word, as the term DMARD had come to do (Fig. 5).Fig. 5

Bottom Line: It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word.Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART).The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

View Article: PubMed Central - PubMed

Affiliation: Department of Social Anthropology, University of Oslo, Blindern, Postboks 1091, 0317, Oslo, Norway, j.k.buer@sai.uio.no.

ABSTRACT
The article outlines a history of the concept of "disease-modifying antirheumatic drugs" or DMARDs--from the emergence in the 1970s of the idea of drugs with decisive long-term effects on bone erosion in rheumatoid arthritis (RA), through the consolidation and popularisation in the term DMARD in 1980s and 1990s. It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word. Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART). The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

No MeSH data available.


Related in: MedlinePlus